Abstract:Background: Inflammation and the excess production of reactive oxygen species (ROS) contribute significantly to the pathogenesis of ischemic retinopathies such as diabetic retinopathy and retinopathy of prematurity. We hypothesized that GKT137831, a dual inhibitor of NADPH oxidases (NOX) 1 and NOX4, reduces inflammation in the ischemic retina by dampening the pro-inflammatory phenotype of retinal immune cells as well as macroglial Müller cells and neurons. Methods: Ischemic retinopathy was induced in Sprague-Dawley rats by exposure to 80 % O2 cycled with 21 % O2 for 3 h per day from postnatal day (P) 0 to P11, followed by room air (P12 to P18). GKT137831 was administered P12 to P18 (60 mg/kg, subcutaneous) and comparisons were to room air controls. Retinal inflammation was examined by measuring leukocyte adherence to the retinal vasculature, ionized calcium-binding adaptor protein-1-positive microglia/macrophages, and the mRNA and protein levels of key inflammatory factors involved in retinal disease. Damage to Müller cells was evaluated by quantitating glial fibrillary acidic protein-positive cells and vascular leakage with an albumin ELISA. To verify the anti-inflammatory actions of GKT137831 on glia and neurons involved in ischemic retinopathy, primary cultures of rat retinal microglia, Müller cells, and ganglion cells were exposed to the in vitro counterpart of ischemia, hypoxia (0.5 %), and treated with GKT137831 for up to 72 h. ROS levels were evaluated with dihydroethidium and the protein and gene expression of inflammatory factors with quantitative PCR, ELISA, and a protein cytokine array. Results: In the ischemic retina, GKT137831 reduced the increased leukocyte adherence to the vasculature, the pro-inflammatory phenotype of microglia and macroglia, the increased gene and protein expression of vascular endothelial growth factor, monocyte chemoattractant protein-1, and leukocyte adhesion molecules as well as vascular leakage. In all cultured cell types, GKT137831 reduced the hypoxia-induced increase in ROS levels and protein expression of various inflammatory mediators. Conclusions: NOX1/4 enzyme inhibition with GKT137831 has potent anti-inflammatory effects in the retina, indicating its potential as a treatment for a variety of vision-threatening retinopathies.

Effect of NADPH oxidase inhibitors in an experimental retinal model of excitotoxicity

Investigation of the Effects of a Novel NOX2 Inhibitor, GLX7013170, against Glutamate Excitotoxicity and Diabetes Insults in the Retina

Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina

Pathophysiology and Therapeutic Potential of NADPH Oxidases in Ischemic Stroke-Induced Oxidative Stress.

Nox2 and Nox4 Participate in ROS-Induced Neuronal Apoptosis and Brain Injury During Ischemia-Reperfusion in Rats

Combined NADPH and the NOX Inhibitor Apocynin Provides Greater Anti-Inflammatory and Neuroprotective Effects in a Mouse Model of Stroke

NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?

NADPH Oxidases in the Central Nervous System: Regional and Cellular Localization and the Possible Link to Brain Diseases

Inhibition of NOX4 with GLX351322 alleviates acute ocular hypertension-induced retinal inflammation and injury by suppressing ROS mediated redox-sensitive factors activation

Pathological high intraocular pressure induces glial cell reactive proliferation contributing to neuroinflammation of the blood-retinal barrier via the NOX2/ET-1 axis-controlled ERK1/2 pathway

Involvement Of Nox2 Nadph Oxidase In Retinal Neovascularization

Diabetic retinopathy: Focus on NADPH oxidase and its potential as therapeutic target

Which NADPH oxidase isoform is relevant for ischemic stroke? The case for nox 2

NADPH OXIDASE NOX2 FACILITATES RETINAL NEOVASCULARISATION IN A MOUSE MODEL OF OXYGEN-INDUCED RETINOPATHY

Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress

NADPH Oxidase: A Potential Target for Treatment of Stroke

Inhibition of Myosin Light Chain Kinase Reduces NADPH Oxidase-Mediated Oxidative Injury in Rat Brain Following Cerebral Ischemia/reperfusion

A Novel Pathway of NADPH Oxidase/vascular Peroxidase 1 in Mediating Oxidative Injury Following Ischemia–reperfusion

NADPH Oxidases: Novel Therapeutic Targets for Neurodegenerative Diseases

Effects of Pharmacological Inhibitors of NADPH Oxidase on Myogenic Contractility and Evoked Vasoactive Responses in Rat Resistance Arteries

The Role of NADPH Oxidases and Oxidative Stress in Neurodegenerative Disorders